To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
The histopathology is limited-stage small cell lung cancer.
ECOG score 0-2.
Good organ function (no blood transfusions, no hematopoietic stimulating factors, no transfusions of albumin or blood products within 14 days prior to the examination).
It is suitable for patients treated with Trilaciclib combined with etoposide plus cisplatin or carboplatin.
Brain metastases with clinical symptoms require local radiotherapy or hormone therapy.
Active infections require systemic treatment.
Subjects with active, known or suspected autoimmune disease or history of autoimmune disease.
Combined with other tumors.
Single group
Trilaciclib
DrugDuring concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
Occurrence of severe neutropenia
Grade 3/4 decline in neutropenia after the first cycle of chemotherapy during radiotherapy
Duration of severe neutropenia
Duration of severe neutropenia after the first cycle of chemotherapy during radiotherapy (ANC\<1.0×10\^9/L for more than 5 days)
Occurrence of hematological toxicity
Grade 3/4 decline in neutrophils, platelets, and red blood cells
Click on the lead sponsor to view all of their trials.
